Separately, HC Wainwright set a $2.80 price objective on Sophiris Bio and gave the company a buy rating in a research note on Monday, October 21st.
SPHS opened at $0.37 on Tuesday. The firm has a market capitalization of $12.92 million, a P/E ratio of -0.71 and a beta of 2.80. Sophiris Bio has a one year low of $0.34 and a one year high of $2.19. The company has a fifty day moving average price of $0.48 and a 200-day moving average price of $0.74.
Sophiris Bio Company Profile
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Read More: Green Investing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.